Please assess the completion status of the following clinical trial:

Trial Title: A Study of CC-99677 in Participants With Active Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Ankylosing Spondylitis (AS) fulfilling the modified New York criteria~* Active axial disease at Screening and Baseline defined by a Bath Ankylosing~* Spondylitis Disease Activity Index (BASDAI) score ≥ 4 and Total Back Pain ≥ 4~* Failed prior treatment with at least 2 NSAIDs for at least 4 weeks each~* Participant has never received a biologic therapy eg, tumor necrosis factor (TNF) antagonist or monoclonal antibody \[mAb\] against IL-17A (biologic naive main study), or have taken more than one biologic therapy (biologic-failure substudy) for the treatment of AS~Exclusion Criteria:~* Radiographic evidence of total ankylosis of the spine~* Clinically significant back pain caused by diseases other than AS~* Concurrent treatment or treatment within the 6 months prior to Baseline with cell depleting biologic agents~* Participation in any study of an investigational drug, including those for COVID-19~* History of malignancy~* Oral corticosteroids (prednisone or equivalent) \> 10 mg/day systemically for ≥ 2 weeks prior to Baseline Visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Administration of CC-99677 150 mg QD PO (Type: EXPERIMENTAL): 49 participants will be randomized to CC-99677 150 mg in biologic naive main study
- Administration of CC-99677 60mg QD PO (Type: EXPERIMENTAL): 49 participants will be randomized to CC-99677 60 mg in biologic naive main study
- Administration of Placebo QD PO (Type: PLACEBO_COMPARATOR): 49 participants will be randomized to placebo in biologic naive main study
- Administration of CC-99677 150 mg QD PO. (Type: EXPERIMENTAL): 20 participants will be randomized to CC-99677 150 mg in biologic-failure substudy
- Administration of CC-99677 60mg QD PO. (Type: EXPERIMENTAL): 20 participants will be randomized to CC-99677 60 mg in biologic-failure substudy
- Placebo additional dose cohort (Type: PLACEBO_COMPARATOR): 10 participants will be randomized to placebo in biologic-failure substudy

Based on this trial design, predict the completion outcome and termination type (if applicable).